Oncosoft
Oncosoft is a Seoul-based medical AI company that develops AI-powered auto-contouring and workflow management software (OncoStudio, OncoFlow) for radiation oncology departments in hospitals. Its solutions serve radiation oncologists and medical physicists across 100+ hospitals globally, reducing manual organ delineation from hours to minutes.
- Company typePrivate
- Founded2019
- HeadquartersSeoul, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Oncosoft does
Oncosoft is a Seoul-based medical AI company developing software for radiation oncology, founded in 2019 by Jin Sung Kim, a Professor of Radiation Oncology at Yonsei University College of Medicine. The company's core product, OncoStudio, performs AI-based automated contouring of normal organs and clinical target volumes from CT and MRI images for radiation therapy treatment planning, processing over 10 million contours for more than 213,000 patients across 100+ hospitals globally. The proprietary technology combines 2D and 3D deep learning with Large Language Model integration for multimodal analysis that incorporates clinical text (disease stage, tumor location, surgical history) alongside imaging data, achieving 2.36x higher accuracy than imaging-only models in external validation. The product suite includes OncoStudio (auto-contouring), OncoFlow (radiotherapy workflow management), OncoPlan (particle therapy treatment planning, in development), OncoRPT/OncoRLT (radiopharmaceutical and radioligand therapy workflow, in development), and OncoVet (veterinary radiation therapy, approved April 2025).
Oncosoft generates revenue primarily through annual or multi-year subscription licenses for hospital deployment, with first commercial revenue in the US and Japan achieved in December 2025. The go-to-market combines direct enterprise sales (Korea, US via Dallas, TX subsidiary established August 2023) with channel partnerships (Anzai Medical holds exclusive Japan distribution rights; M3 AI provides marketing network access in Japan). Regulatory clearance across Korea (MFDS, February 2022), US (FDA 510(k), February 2025), Japan (PMDA, April 2025), Singapore (October 2025), and Brazil (December 2025) enables multi-market commercialization, supported by ISO 13485, ISO 27001, and ISO 27701 certifications. Customers include major Korean cancer centers (Samsung Seoul Hospital, Seoul National University Hospital, Severance Hospital, Kangbuk Samsung Hospital), Mayo Clinic (US flagship, 10 licenses), and research institutions in Japan and Singapore.
The company has raised approximately 150 billion KRW (~$112M USD) cumulatively across seed, pre-A, Series A (35B KRW in September 2022), and Series B (11B KRW in September 2024) rounds, with investors including BNH Investment, HB Investment, Devsisters Ventures, BonAngels Venture Partners, and LB Investment. Total headcount is 11-50, with leadership comprising CEO Jin Sung Kim, CTO Han Joo Chae, CPO Seonggong Moon, CFO Yeonkyung Lee, and Sales Director Do-il Jung, plus three medical advisors. Oncosoft is targeting an IPO in 2026 and has executed pre-IPO corporate actions including a stock split (November 2024), third-party share allocation, and free share distribution.
Oncosoft firmographics
Firmographics- Name
- Oncosoft
- Legal name
- Oncosoft Inc.
- Website
- https://oncosoft.io
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Oncosoft is a Seoul-based medical AI company that develops AI-powered auto-contouring and workflow management software (OncoStudio, OncoFlow) for radiation oncology departments in hospitals. Its solutions serve radiation oncologists and medical physicists across 100+ hospitals globally, reducing manual organ delineation from hours to minutes.
- Ownership category
- akta.pro rank
Oncosoft industry classification
Industry- Product category
- Radiation Oncology AI Software
- NAICS
- Diagnostic Imaging Centers (621512), Medical and Diagnostic Laboratories (6215), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Oncology Telemedicine Platforms (HLALAGAH)
- akta.pro secondary industries
- Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI), Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB), Radiation Oncology (HLAKAFAC)
Keywords
Where Oncosoft is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices3 records
Markets served
Oncosoft business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Software Licenses (OncoStudio, OncoFlow): Annual or multi-year license fees for AI contouring and workflow management software. Revenue recognized from hospital deployments in Korea (20+ hospitals), US (Mayo Clinic), Japan, Singapore, and other markets. First commercial revenue in US and Japan achieved December 2025.
- Treatment Planning Systems (OncoPlan): Treatment planning software for particle therapy (proton, heavy ion) under development. Planned commercialization by 2027 targeting particle therapy centers worldwide.
- Radiopharmaceutical Therapy (RLT) Platform: Web-based platform for radioligand therapy planning and workflow management under development. Targets emerging RLT treatments including Pluvicto and future radiopharmaceuticals.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise hospital licensing |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels6 records
Oncosoft product offering
Product offeringCore offering
Oncosoft develops and sells AI-based software for radiation oncology. Its core product OncoStudio performs automated contouring of normal organs and clinical target volumes from CT and MRI images, reducing contouring time from hours to about one minute per case. The company also offers OncoFlow for radiotherapy workflow management and is developing OncoPlan (particle therapy treatment planning), OncoRPT (radiopharmaceutical therapy workflow), and OncoVet (veterinary radiation therapy) for sale to hospitals and cancer centers.
Product overview
Oncosoft offers an end-to-end AI software ecosystem for radiation oncology, consisting of OncoStudio (AI auto-contouring) as the core commercial product, OncoFlow (workflow management) for treatment process integration, and pipeline products including OncoPlan (particle therapy planning), OncoRPT (radiopharmaceutical therapy workflow), and OncoRLT (radioligand therapy). The portfolio also includes OncoVet for veterinary applications. The products work together to provide comprehensive coverage from automated organ segmentation through treatment planning and workflow management across the entire radiotherapy process.
Differentiator
Problem solved
Functional benefit
Brands
- OncoStudio: AI-powered automatic contouring software for radiation therapy that automatically identifies and segments organs and tissues from CT and MRI images to support treatment planning
- OncoFlow
- OncoPlan
- OncoRPT
- OncoVet
Products and services
- OncoStudio AI-based automated contouring software that automatically segments normal organs and clinical target volumes from CT and MRI images for radiation therapy planning. Reduces contouring time from hours to approximately 1 minute per case while maintaining expert-level accuracy. Supports 190+ structures for head and neck, thorax, abdomen, and pelvis. Targeted at radiation oncology departments in hospitals and cancer centers globally.
- OncoFlow Comprehensive radiotherapy workflow management platform that integrates the entire treatment process into one seamless system, eliminating errors and streamlining every treatment step from patient data management to treatment delivery. Targeted at hospital radiation oncology departments and cancer centers.
- OncoPlan AI-guided treatment planning software for particle therapy that optimizes dose calculations using biophysical simulation, maximizing tumor control while minimizing damage to surrounding organs for proton and heavy ion radiotherapy. Targeted at particle therapy centers globally.
- OncoRPT Radiopharmaceutical Therapy (RPT) workflow management platform providing personalized dosimetry and integrated patient monitoring to improve treatment precision and safeguard healthy tissues for emerging radiopharmaceutical treatments. Targeted at cancer centers offering radiopharmaceutical therapy.
- OncoVet (OncoBet) Veterinary radiation therapy software providing AI-based contouring and treatment planning for animal cancer patients in veterinary oncology settings. Targeted at veterinary hospitals and animal cancer centers.
Quantifiable outcome
- Reduces contouring time from hours to ~1 minute per case (10x faster)
- +4 more outcomes
Companies that use Oncosoft
Customer profileNamed customers10 records
Segments3 records
Ideal customer profiles2 records
Oncosoft technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability8 records
Feature6 records
Oncosoft partnerships and signals
Strategic signalScale indicators10 records
Recent moves9 records
Expansion highlights6 records
Oncosoft competitors and assessment
Company assessmentDirect peers
- RaySearch Laboratories: Swedish public company specializing in radiation oncology treatment planning software (RayStation, RayCare). Direct competitor in radiation therapy software with global installed base across major cancer centers.
- MVision AI: Finnish company providing AI-based auto-segmentation for radiation therapy planning. Closest direct competitor to OncoStudio in AI auto-contouring, with CE-marked and FDA-cleared products.
- Limbus AI: Canadian AI auto-contouring company (Limbus Contour) for radiation oncology. Direct competitor targeting the same hospital radiation oncology departments with similar AI segmentation products.
- Mirada Medical: UK-based medical imaging AI company with products for radiation oncology workflow including auto-contouring and treatment planning. Direct peer in oncology imaging AI space.
- MIM Software: US medical imaging analysis software company with products for radiation oncology including contouring and image registration. Direct peer in radiation oncology AI software with hospital channel.
Emerging players
- TheraPanacea: French AI company applying deep learning to radiation oncology treatment planning and auto-contouring. Comparable emerging player targeting similar radiation oncology AI use cases in Europe.
- Radformation: US-based radiation oncology automation software company (ClearCalc, AutoContour, EZFluence). Comparable peer providing AI-driven workflow automation tools to radiation oncology departments.
- Pursuit Healthcare Advisors / Adaptiiv: Emerging players in radiation oncology software including 3D printing and AI-based planning tools. Adjacent to Oncosoft's expanding radiation therapy planning product portfolio.
Broad incumbents
- Varian Medical Systems (Siemens Healthineers): Largest radiation oncology software and equipment vendor globally (now owned by Siemens Healthineers). Broad incumbent offering Ethos adaptive radiotherapy and Eclipse treatment planning with embedded AI features; Oncosoft has MOU partnership with Elekta but competes with Varian's full stack.
- Elekta: Global radiation therapy equipment and software vendor (Mosaiq, Versa HD, Unity MR-Linac). Oncosoft has an established MOU/partnership with Elekta; broad incumbent serving the same radiation oncology customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Customer concentration
Oncosoft social profiles
Digital presenceOncosoft compliance and trust
Trust signalCompliance8 records
Oncosoft financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oncosoft leadership team
Management profileNumber of profiles
Profiles8 records
Oncosoft subsidiaries and ownership
Company hierarchySubsidiaries1 record
Oncosoft funding detail
Funding detailFunding overview
Funding rounds5 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oncosoft M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oncosoft
What does Oncosoft do?
Oncosoft develops and sells AI-based software for radiation oncology. Its core product OncoStudio performs automated contouring of normal organs and clinical target volumes from CT and MRI images, reducing contouring time from hours to about one minute per case. The company also offers OncoFlow for radiotherapy workflow management and is developing OncoPlan (particle therapy treatment planning), OncoRPT (radiopharmaceutical therapy workflow), and OncoVet (veterinary radiation therapy) for sale to hospitals and cancer centers.
Is Oncosoft a public or private company?
Oncosoft is a private company. It is classified as venture growth investor backed and is currently operating.
When was Oncosoft founded?
Oncosoft was founded in 2019. It employs 11 to 50 people.
Where is Oncosoft based?
Oncosoft is headquartered in Seoul, South Korea, in the Asia region.
How does Oncosoft make money?
Three revenue lines are on record. Software Licenses (OncoStudio, OncoFlow) is the primary driver. The others are treatment Planning Systems (OncoPlan) and radiopharmaceutical Therapy (RLT) Platform.
Who are Oncosoft's main competitors?
Direct peers on record are RaySearch Laboratories, MVision AI, Limbus AI, Mirada Medical and MIM Software. Emerging players are TheraPanacea, Radformation and Pursuit Healthcare Advisors / Adaptiiv. Broad incumbents are Varian Medical Systems (Siemens Healthineers) and Elekta.
Does Oncosoft have an API?
No public API is recorded for Oncosoft.
What industry is Oncosoft in?
Oncosoft's product category is Radiation Oncology AI Software. Its primary akta.pro industry code is HLALAGAH, Oncology Telemedicine Platforms, with a secondary code of HLAIAGAI, Nuclear Medicine Clinical Services & Therapy Centers. Its NAICS code is 621512 and its SIC code is 2834.